dr mark gordon glutathione Dr. Mark Gordon - Medical Director

Following administration in animal models: BPC-157 demonstrates rapid systemic distribution within 15-30 minutes with unusual oral bioavailability TB-500 shows tissue-specific accumulation with preferential uptake in injured areas GHK-Cu exhibits copper-mediated transport and gene-modulating tissue binding KPV utilizes PepT1 transporter-mediated uptake with enhanced delivery to inflamed tissues Combined formulation provides immediate, sustained, and targeted bioactivity across multiple mechanisms Distribution studies suggest that injury sites and inflamed tissues tend to concentrate multiple components through different mechanisms BPC-157 through injury-site targeting, TB-500 through actin-rich repair zones, GHK-Cu through copper-dependent pathways, and KPV through upregulated PepT1 in inflammation, potentially enhancing local therapeutic effects

Glutathione Unfortunately, glutathione supplements are fully metabolized in the stomach and gut, making them an ineffective source of plasma glutathione

This is a key distinction in the Matrixyl vs GHK-Cu landscape

confirmed that in MCF-7 cells, which a low aggressive breast cancer cell line, the expression of GPx2 can be substantially up-regulated by retinoic acid [94]

[1] [3] The compounded nature of this product allows for individualized dosing and administration, which may be advantageous in clinical scenarios where standardized commercial products are not available or appropriate

Barrier compromise symptoms, including increased sensitivity to other products, unusual dryness, or flakiness, suggest copper peptide concentration is overwhelming skin's repair capacity